Personal Information. Language Skills. Address. Telephone. . Language Read Write Speak Understand English Yes Yes Yes Yes French Yes Yes Yes Yes

Transcription

1 Protected when completed This is a draft version only. Do not submit to any funding organization. Only the final version from the History page can be submitted. It is strictly forbidden to submit this draft version to an organization that is not a member of the CCV. The complete list of CCV members is available at Personal Information Identification Correspondence language: English Sex: Male Date of Birth: 8/25 Canadian Residency Status: Canadian Citizen Country of Citizenship: Canada Language Skills Language Read Write Speak Understand English Yes Yes Yes Yes French Yes Yes Yes Yes Address The primary address is denoted by (*) Courier Primary Affiliation (*) CRCHUM Hôtel-Dieu 3850 St. Urbain Street Masson Pavilion, Rm Montréal H2W 1T7 Canada, Quebec CRCHUM Hôtel-Dieu 3850 St. Urbain Street Masson Pavilion, Rm Montréal H2W 1T7 Canada, Quebec Telephone The primary telephone is denoted by (*) Fax Work extension: Work (*) extension: The primary is denoted by (*) Work (*) jean.louis.chiasson@umontreal.ca 1

2 User Profile DRAFT Disciplines Trained In: Endocrinology Research Disciplines: Endocrinology Areas of Research: Diabetes, Hormonal Regulation, Metabolism, Nutrition, Pharmacoepidemiology Fields of Application: Biomedical Aspects of Human Health, Pathogenesis and Treatment of Diseases Research Specialization Keywords: carbohydrate metabolism, complications, diabetes melllitus, glucagon secretion/action, glucose turnover, insulin secretion/action, isotopic technique, nutrition/ treatment, organ perfusion, prevention Education Degrees 1970/7-1975/7 Diploma - Certification - Endocrinology - McGill University - Completed 1967/7-1968/7 Doctorate - LMCC - M.D. - Endocrinologist - Medical Research Council of Canada - Completed 1963/9-1967/7 Doctorate - M.D. - Medical Doctor - Université Laval - Completed 1961/9-1963/7 Bachelor's - B.A. - Chemistry - Sainte-Anne - Completed Employment Academic Work Experience 1992/10 - Chief, Research Group on Diabetes and Metabolic Regulation CRCHUM 1992/7 - Full Professor Université de Montréal - Médecine 1980/7 - Endocrinologist CHUM Affiliations The primary affiliation is denoted by (*) (*) 1992/7 - Full Professor - Médecine - Université de Montréal Research Funding History Awarded 2012/5-2019/5 The effect of dulaglutide on major cardiovascular events in patients with type 2 diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND). : Jean-Louis Chiasson 2

3 2012/6-2017/6 2011/4-2016/4 2010/1-2015/1 2012/5-2014/5 2011/7-2013/7 DRAFT 2012/5-2019/5 Clinical randomized trial Eli Lilly Canada Inc. Total Funding: (Canadian dollar) Determinants of increased risk of cardio-vascular diseases in HIV-infected individuals. 2012/6-2017/6 Subvention d'équipe: VIH/sida et comorbidités Canadian Institutes of Health Research (CIHR) Total Funding: (Canadian dollar) Étude de phase IV multicentrique, à répartition aléatoire et à double insu avec contrôle par placebo visant à évaluer l effet de la saxagliptine sur l incidence du décès d origine cardiovasculaire, de l infarctus du myocarde ou de l AVC ischémique.. Co-investigator : Sophie Bernard 2011/4-2016/4 AstraZeneca Canada Inc. Total Funding: (Canadian dollar) TECOS: A randomized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with sitagliptin in patients with type 2 diabetes mellitus and inadequate glycemic control on mono- or dual combination on oral... : Chiasson, Jean-Louis;Étude multicentrique; 2009/ /11 Clinical trial Merck & Co. Inc Total Funding: (Canadian dollar) The impact of LY versus insulin glargine for patients with type 1 diabetes mellitus treated with preprandial insulin lispro: a double-blind, randomized, 52-week study. The IMAGINE 3 Study. Co-investigator : Sophie Bernard 2012/5-2014/5 Clinical randomized trial Eli Lilly Canada Inc. Total Funding: (Canadian dollar) A 24-week, multicenter, international, randomized (1:1), parallel-group, openlabel, comparative study of insulin glargine versus liraglutide in insulin-naive patients with type 2 diabetes trated with oral agents and not adequately controlled with... Co-investigator : Sophie Bernard 3

4 2012/7-2013/6 Applicant 2012/5-2013/5 2010/3-2013/3 2011/2-2013/2 2011/4-2012/4 DRAFT 2011/7-2013/7 Sanofi-aventis Total Funding: (Canadian dollar) Quelle est l'évidence justifiant la recommandation d'utiliser 1 mg de glucagon pour corriger l'hyperglycémie sévère chez le sujet avec diabète de type 1? Applicant : Jean-Louis Chiasson 2012/7-2013/6 Diabetes Québec Total Funding: (Canadian dollar) 6-month, multicenter, randomized, open-label, parallel-group study comparing the efficacy and safety of a new formulation of insulin glargine and Lantus both plus mealtime insulin in patients with type 2 diabetes mellitus with a 6-mo safety extension Co-investigator : Sophie Bernard 2012/5-2013/5 Clinical randomized trial Sanofi-aventis Total Funding: (Canadian dollar) Autogestion du diabète et dépression : Marie-Dominique Beaulieu 2010/3-2013/3 Operating grant Canadian Institutes of Health Research (CIHR) Total Funding: (Canadian dollar) A randomized, doule-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, and tolerability of canagliflozin compared with placebo in the treatment of older subjects with type 2 diabetes mellitus inadequately.. Co-investigator : Sophie Bernard 2011/2-2013/2 Clinical trial, Janssen Inc. Janssen-Ortho Inc. Total Funding: (Canadian dollar) A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI (10 mg and 25 mg once daily) and sitagliptin (100 mg once daily) given for a minimum of 76 weeks (incl. 24 weeks of preceding trial)... Co-investigator : Sophie Bernard 4

5 2010/1-2011/1 DRAFT 2011/4-2012/6 Clinical trial, Boehringer Ingelheim Boehringer Ingelheim Total Funding: (Canadian dollar) VIH et prévention des comorbidités: Adapter et valider une intervention virtuelle visant à réduire les facteurs de risque liés aux maladies cardiovasculaires et au diabète chez les personnes vivant avec le VIH. : Josée Coté 2010/1-2011/1 Operating grant Canadian Institutes of Health Research (CIHR) Total Funding: (Canadian dollar) Completed 2011/1-2012/1 2007/7-2011/7 2010/9-2011/3 2010/1-2011/1 A randomized trial evaluating the effect of liraglutide versus insulin glargine on hepatic steatosis as measured by MRI and MRS in metformin-treated patients with type 2 diabetes. : An Tang 2010/1-2011/1 RSNA R&E Foundation Fonds de la Recherche en Santé du Québec (FRSQ) Total Funding: (Canadian dollar) Rigorous evaluation and integration medicine in aboriginal diabetes care. : Pierre Haddad 2007/7-2011/7 Team in Traditional Aboriginal Plants Against Diabetes Canadian Institutes of Health Research (CIHR) Total Funding: (Canadian dollar) A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI (10 mg, 25 mg) administered orally, once daily over 24 weeks in patients with type 2 diabetes mellitus with insufficient glycemic control. Co-investigator : Sophie Bernard 2010/9-2011/3 Clinical trial, Boehringer Ingelheim Boehringer Ingelheim Total Funding: (Canadian dollar) Essai randomisé du liraglutide versus l'insuline glargine sur la stéatose hépatique... : An Tang 5

6 2010/1-2011/1 2007/7-2010/7 2009/1-2010/1 2007/7-2009/7 2007/6-2008/12 DRAFT 2010/1-2011/1 Diabetes Québec Total Funding: (Canadian dollar) Essai randomisé du liraglutide versus l'insuline glargine sur la stéatose hépatique mesurée par résonance magnétique chez les patients atteints de diabète de type 2 traités à la metformine. : Tang, An;Dr Jean-Louis Chiasson 2010/1-2011/1 Canadian Heads of Academic Radiology (CHAR) Total Funding: 7500 (Canadian dollar) Estimating the prevalence of diabetes using multiple tests: A validation of the national diabetes surveillance system definition. : Elham Rahme 2007/7-2010/7 INMD Diabetes Surveillance Systems/CIHR Canadian Institutes of Health Research (CIHR) Total Funding: (Canadian dollar) Innovation in cardiovascular imaging and image-guided therapy to improve patient management. : Gilles Soulez 2009/1-2010/1 FCI Canada Foundation for Innovation (CFI) Total Funding: (Canadian dollar) The DREAM On Study (an observational study). Diabetes REduction Assessment with ramipril and rosiglitazone Medication Ongoing evaluation. : Hertzel C. Gerstein 2007/7-2008/7 Clinical Trial Canadian Institutes of Health Research (CIHR) Total Funding: (Canadian dollar) A multicenter, randomized, double-blind study to evaluate the safety and efficacy of the addition of sitagliptin (MK-0431) to patients with type 2 diabetes mellitus who have inadequate glycemic control on insulin therapy (alone or in combination... Co-investigator : Rémi Rabasa-Lhoret 2007/6-2008/12 Merck Frosst Canada Inc Total Funding: (Canadian dollar) 6

7 2007/ /11 A 12-week, randomized, multicenter, double-blind, placebo-controlled study, assessing the safety and efficacy of ID1101 in obese patients Co-investigator : Rémi Rabasa-Lhoret 2007/ /11 Innodia Inc. Total Funding: (Canadian dollar) Activities Supervisory Activities Student/Postdoctoral Supervision Co-Supervisor Supervisor Co-Supervisor Co-Supervisor Supervisor Supervisor Sima Aurelia - Doctorate - Université de Montréal - In Progress Student Degree Start Date: 2009/1 Student Degree Expected Date: 2013/6 Project Description: L acide rétinoïque dans l obésité et le diabète de type 2 Present Position: Ph.D. Student Lorena Iglesias - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 2009/1 Student Degree Received Date: 2011/6 Project Description: Évaluation d'un prototype d'un détecteur de glucose photonique. Present Position: public sector Constantin Manolescu Daniel - Doctorate - Université de Montréal - In Progress Student Degree Start Date: 2009/1 Student Degree Expected Date: 2013/6 Project Description: Retinoic acid and insulin resistance in the development of type 2 diabetes Present Position: Ph.D. Student Janie Houle, - Post-doctorate - UQAM - Completed Student Degree Start Date: 2007/1 Student Degree Received Date: 2011/12 Project Description: Impact de la dépression sur les comportements d'autogestion du diabète Present Position: academic sector Zebdi Samia - Bachelor's - UQTR - Completed Student Degree Start Date: 2007/1 Student Degree Received Date: 2007/4 Project Description: Le rôle de l'hyperglycémie post-prandiale dans les complications coronariennes Brindisi Marie-Claude - Post-doctorate - CHU Bocage (Dijon, France) - Completed Student Degree Start Date: 2004/12 Student Degree Received Date: 2007/4 Project Description: Effets de l'acarbose et du répaglinide sur le stress oxydatif... Present Position: Endocrinologist, Dijon (France) 7

8 Supervisor Supervisor Co-Supervisor Supervisor Supervisor Geneviève Beauregard, - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 2003/1 Student Degree Received Date: 2005/1 Project Description: Étude de la régulation de l'expression des gènes par l'insuline et le glucose Demiana Ekladous, - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 2003/1 Student Degree Received Date: 2005/6 Project Description: Hepatic resistance to glucagon Amélie Pelletier, - Doctorate - Université de Montréal - Completed Student Degree Start Date: 2000/6 Student Degree Received Date: 2006/6 Project Description: Regulation of glucose uptake in cardiomyocytes Present Position: Research Coordinator Sandra Bérubé, - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 2000/6 Student Degree Received Date: 2003/7 Project Description: Insulin sensitivity in a healthy population Present Position: private sector Yamina Boukhors, - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 1998/9 Student Degree Received Date: 2003/8 Project Description: Use of information technology for management of ITT in type 1 diabetes Present Position: other International Collaboration Activities Member Contributions Presentations United Kingdom Activity Description: The Acarbose Cardiovascular Evaluation (ACE) Trial "Prevention of diabetes: Are we there yet?", At the Heart of Diabetes. An Essential Primer for Cardiovascular Renal and Metabolic Risk Reduction in Diabetes., Canada, Ontario, Toronto Invited?: Yes Vincent Poitout, "La glucotoxicité et la lipotoxicité dans le développement du diabète de type 2 et des complications vasculaires : approches fondamentales et cliniques.", Séminaire de la direction scientifique, Département de médecine, CHUM, Canada, Quebec, Montreal Invited?: Yes 8

9 "Lignes directrices de pratique clinique pour la prévention et le traitement du diabète 2013", Endocrine Grand Round, Division of Endocrinology, CHUM, Canada, Quebec, Montreal Invited?: Yes "Pré-diabète: fault-il le traiter?", Congrès de la Société Francophone du diaète 2013, France, Montpellier Invited?: Yes "Treatment of diaetes mellitus and the vascular complications.", SANOFI Guest speaker, Canada, Quebec, Laval Invited?: Yes "Treating postprandial hyperglycaemia for the prevention of cardiovascular disease.", National Atherosclerosis and Cardiometabolic Forum, Canada, Ontario, Toronto Invited?: Yes "Les complications vasculaires du diabète de type 2: peut-on les freiner?", Eli Lilly Guest Speaker, Canada, Quebec, Montreal Invited?: Yes "Mieux traiter les troubles métaboliques des patients VIH en 2012.", Dépistage et gestion du diabète chez le patient VIH, Canada, Quebec, Montréal Invited?: Yes "Treating postprandial plasma glucose for the prevention of diabetes and CVD: the STOP-NIDDM Trial.", Bayer Scientific Meeting., China, Beijing : Bayer HealthCare AG "La glycémie postprandiale et le risque cardiovasculaire.", Bayer Scientific Symposium, Tunisia, Djerba : Bayer AG "Le rôle des incrétines dans le diabète de type 2.", 21e Congrès National d'endocrinologie de la Société Tunisienne d'endocrinologie, Diabète et Maladies Métaboliques, Tunisia, Tunis : Bayer AG "Le traitement de l'hyperglycémie postprandiale pour la prévention du diabète et des complications cardiovasculaires.", 21e Congrès National d'endocrinologie de la Société Tunisienne d'endocrinologie, Diabète et Maladies Métaboliques, Tunisia, Tunis : Bayer AG - 0 9

10 "La glycémie et le risque cardiovasculaire.", Bayer Guest Speaker, Tunisia, Tunis : Bayer AG "La glycémie postprandiale et le risque cardiovasculaire.", Bayer Guest Speaker, Tunisia, Sfax : Bayer AG "Disposition index and the conversion of IGT to diabetes mellitus: The STOP- NIDDM Trial.", International Diabetes Federation 2011 (IDF 2011). Session: Insulin resistance in young and old., United Arab Emirates, Dubai "Le rôle de la microflore intestinale dans le développement de l'obésité.", Guest Speaker Sanofi, Scientific Grand Round, Division of Endocrinology, CHUM, Canada, Quebec, Montréal "Glucose control and cardiovascular disease.", ACE Regional Meeting, Speaker Tour, China, Guangzhou "Glucose control and cardiovascular disease.", ACE Regional Meeting, Speaker Tour., China, Hangzhou "Traiter l'hyperglycémie postprandiale pour la prévention du diabète et des complications vasculaires.", Sanofi Aventis Guest speaker, Division of Endocrinology, Montreal Jewish Hospital., Canada, Quebec, Montreal "Traiter l'hyperglycémie postprandiale pour diminuer le risque de diabète et de ses complications vasculaires.", Bayer Workshop., France, Nice "How to achieve safe and long-term glycaemic control with cardiovascular benefits.", Bayer Schering Pharma, 2nd Cardiovascular Risk Management Symposium. The Challenge of Cardiovascular Disease Prevention., France, Nice "CSN Debate: Hemoglobin A1C should be normalized with intensive insulin therapy to prevent macro- and microvascular disease in type 2 diabetes. Affirmative: Jean-Louis Chiasson, Negative: Richard Gilbert", Canadian Society of Nephrology Annual General Meeting 2010., Canada, Quebec, Montreal "L'hyperglycémie post-prandiale, son rôle délétère et sa prise en charge.", Congrès annuel de la Société Algérienne de Diabétologie., Algeria, Alger "La prévention du diabète de type 2.", Congrès annuel de la Société Algérienne de Diabétologie., Algeria, Alger 10

11 "Evidence for CV benefits with acarbose intervention.", Bayer Schering Pharma Asia-Pacific Cardiovascular Risk Management Expert Workshop., Taiwan, Province of China, Taipei "Effects of oral diabetic drugs on CVD.", Bayer Schering Pharma Asia-Pacific ACE Speaker. Training Workshop., Taiwan, Province of China, Taipei "Atteindre les cibles en diabète: Nouvelles options pour l'insulinothérapie.", Sanofi Aventis Guest Speaker. Division of Endocrinology, Montreal Jewish Hospital., Canada, Quebec, Montreal "Guest speaker and Chairman: Intervention multifactorielle dans le traitement du diabète de type 2.", Optimizing long-term glycemic control in type 2 diabetes: Overcoming a progressive pathophysiology with incretin therapie (WorldWIDE), Symposium during the 20th IDF World Diabetes Congress., Canada, Quebec, Montreal "Debate on Primary prevention programmes for diabetes: lifestyle versus drugs - Drugs.", 20th IDF World Diabetes Congress., Canada, Quebec, Montreal "Guest speaker and Chairman. Glucose lowering interventions in diabetes and CVD - lessons from outcome studies.", Bayer Healthcare Satellite Symposium, 20th IDF World Diabetes Congress, Canada, Quebec, Montreal "Traiter l'hyperglycémie postprandiale pour diminuer le risque de diabète et de ses complications vasculaires.", Bayer Healthcare Meet the Expert Session, 20th IDF World Diabetes Congress., Canada, Quebec, Montreal "Postprandial peak reduction and its implication in the prevention of CV risk and diabetes.", Congress of Obesity, Metabolic Syndrome and Prediabetes., Venezuela, Bolivarian Republic of, Caracas "La prévention du diabète de type 2 et de ses complications.", Guest speaker Eli Lilly, Division of Endocrinology., Canada, New Brunswick, Moncton "Stratégies de sensibilisation à l'insuline et d'apport d'insuline dans le traitement du diabète de type 2. Quand et pourquoi?", Diabetes Forum., Canada, Quebec, Montreal "Postprandial plasma glucose as a risk factor for cardiovascular disease.", Endocrine Grand Round, Division of Endocrinology, University of Toronto., Canada, Ontario, Toronto "The benefits of early insulin as opposed to oral hypoglycemic agents in type 2 diabetes.", Canadian Society of Endocrinology and Metabolism., Canada, Ontario, Toronto

12 "L'insulinothérapie : Initiation pratique et nouvelles insulines.", SSVQ Symposium (Société des sciences vasculaires du Québec) - Le diabète: démystifier l'insulinothérapie et les nouveaux hypoglycémiants oraux., Canada, Quebec, Montreal Interviews and Media Relations Broadcast Interviews Publications PubMed Articles Type 2 diabetes "Les docteurs" - Radio-Canada Chiasson JL, "Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial.", Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 12 Suppl 1 PubMed ID: Althouse AD, Abbott JD, Sutton-Tyrrell K, Forker AD, Lombardero MS, Buitrón LV, Pena-Sing I, Tardif JC, Mori Brooks M,, "Favorable Effects of Insulin Sensitizers Pertinent to Peripheral Arterial Disease in Type 2 Diabetes: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.", Diabetes care PubMed ID: Leong A, Dasgupta K, Chiasson JL, Rahme E, "Estimating the Population Prevalence of Diagnosed and Undiagnosed Diabetes.", Diabetes care PubMed ID: Tamis-Holland JE, Lu J, Korytkowski M, Magee M, Rogers WJ, Lopes N, Mighton L, Jacobs AK,, "Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revasc", Journal of the American College of Cardiology, 61(17) PubMed ID: Farkouh ME, Boden WE, Bittner V, Muratov V, Hartigan P, Ogdie M, Bertolet M, Mathewkutty S, Teo K, Maron DJ, Sethi SS, Domanski M, Frye RL, Fuster V, "Risk factor control for coronary artery disease secondary prevention in large randomized trials.", Journal of the American College of Cardiology, 61(15) PubMed ID: Ismail-Beigi F, Lombardero MS, Escobedo J, Genuth S, Green J, Massaro E, Mooradian AD, Ovalle F, Whitehouse F, Zonszein J,, "Determinants of successful glycemic control among participants in the BARI 2D Trial: A Post-hoc Analysis.", Journal of diabetes and its complications PubMed ID:

13 Wolever, T.M.S., Gibbs, A.L., Chiasson, J.L., Connelly, P.W., Josse, R.G., Leiter, L.A., Maheux, P., Rabasa-Lhoret, R., Rodger, N.W., Ryan, E.A., "Altering source or amount of dietary carbohydrate has acute and chronic effects on postprandial glucose and triglycerides in type 2 diabetes: Canadian trial of Carbohydrates in Diabetes (CCD).", Nutr. Metab. Cardiovasc. Dis., 23 PubMed ID: Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S, Bertrand M, Fuster V,, "Strategies for multivessel revascularization in patients with diabetes.", The New England journal of medicine, 367(25) PubMed ID: Bergenstal RM, Forti A, Chiasson JL, Woloschak M, Boldrin M, Balena R, "Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial).", Diabetes therapy : research, treatment and education of diabetes and related disorders, 3(1) PubMed ID: Hanefeld M, Pistrosch F, Koehler C, Chiasson JL, "Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trial.", Journal of hypertension, 30(7) PubMed ID: Henderson M, Baillargeon JP, Rabasa-Lhoret R, Chiasson JL, Hanley J, Lambert M, "Estimating insulin secretion in youth using simple indices derived from the oral glucose tolerance test.", Diabetes & metabolism PubMed ID: Wolever TM, Gibbs AL, Chiasson JL, Connelly PW, Josse RG, Leiter LA, Maheux P, Rabasa-Lhoret R, Rodger NW, Ryan EA, "Altering source or amount of dietary carbohydrate has acute and chronic effects on postprandial glucose and triglycerides in type 2 diabetes: Canadian trial of Carbohydrates in Diabetes (CCD).", Nutrition, metabolism, and cardiovascular diseases : NMCD PubMed ID: Broderick TL, El Midaoui A, Chiasson JL, Wang D, Jankowski M, Gutkowska J, "The effects of exercise training on #-butyrobetaine hydroxylase and novel organic cation transporter-2 gene expression in the rat.", Applied physiology, nutrition, and metabolism = Physiologie appliquée, nutrition et métabolisme, 36(6) PubMed ID: "Incidence of diabetes following ramipril or rosiglitazone withdrawal.", Diabetes care, 34(6) PubMed ID: Gerstein HC, Mohan V, Avezum A, Bergenstal RM, Chiasson JL, Garrido M, MacKinnon I, Rao PV, Zinman B, Jung H, Joldersma L, Bosch J, Yusuf S, "Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.", Diabetologia, 54(3) PubMed ID:

14 Singh PP, Abbott JD, Lombardero MS, Sutton-Tyrrell K, Woodhead G, Venkitachalam L, Tsapatsaris NP, Piemonte TC, Lago RM, Rutter MK, Nesto RW,, "The prevalence and predictors of an abnormal ankle-brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.", Diabetes care, 34(2) PubMed ID: Henderson M, Rabasa-Lhoret R, Bastard JP, Chiasson JL, Baillargeon JP, Hanley JA, Lambert M, "Measuring insulin sensitivity in youth: How do the different indices compare with the gold-standard method?", Diabetes & Metabolism, 37(1) PubMed ID: Tuomilehto J, Lindström J, Hellmich M, Lehmacher W, Westermeier T, Evers T, Brückner A, Peltonen M, Qiao Q, Chiasson JL, "Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-the STOP-NIDDM riskscore.", Diabetes research and clinical practice, 87(2) PubMed ID: Chiasson JL, "Early insulin use in type 2 diabetes: what are the cons?", Diabetes care, 32 Suppl 2 PubMed ID: de Galan BE, Zoungas S, Chalmers J, Anderson C, Dufouil C, Pillai A, Cooper M, Grobbee DE, Hackett M, Hamet P, Heller SR, Lisheng L, Macmahon S, Mancia G, Neal B, Pan CY, Patel A, Poulter N, Travert F, Woodward M,, "Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.", Diabetologia, 52(11) PubMed ID: Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, MacMahon S, Marre M, Neal B, Patel A, Woodward M, Chalmers J,, Cass A, Glasziou P, Harrap S, Lisheng L, Mancia G, Pillai A, Poulter N, Perkovic V, Travert F, "Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.", Diabetes care, 32(11) PubMed ID: Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE, "A randomized trial of therapies for type 2 diabetes and coronary artery disease.", The New England journal of medicine, 360(24) PubMed ID: Hammana I, Coderre L, Potvin S, Costa M, Berthiaume Y, Lavoie A, Chiasson JL, Levy E, Rabasa-Lhoret R, "Dichotomy between postprandial glucose and lipid profiles in adults with cystic fibrosis: a pilot study.", Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 8(2) PubMed ID:

15 Pop-Busui R, Lu J, Lopes N, Jones TL,, "Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.", Journal of the peripheral nervous system : JPNS, 14(1) PubMed ID: Hanefeld M, Karasik A, Koehler C, Westermeier T, Chiasson JL, "Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.", Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease, 6(1) PubMed ID: Sreenan S, Virkamäki A, Zhang K, Hansen JB,, "Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study.", International journal of clinical practice, 62(12) PubMed ID: Godbout A, Hammana I, Potvin S, Mainville D, Rakel A, Berthiaume Y, Chiasson JL, Coderre L, Rabasa-Lhoret R, "No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes.", Diabetes & metabolism, 34(6 Pt 1) PubMed ID: Wolever TM, Mehling C, Chiasson JL, Josse RG, Leiter LA, Maheux P, Rabasa-Lhoret R, Rodger NW, Ryan EA, "Low glycaemic index diet and disposition index in type 2 diabetes (the Canadian trial of carbohydrates in diabetes): a randomised controlled trial.", Diabetologia, 51(9) PubMed ID: "Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.", American heart journal, 156(3) PubMed ID: Ekladous D, Mehdi MZ, Costa M, Srivastava AK, Chiasson JL, Coderre L, "Tissue- and fibre-specific modifications of insulin-signalling molecules in cardiac and skeletal muscle of diabetic rats.", Clinical and experimental pharmacology & physiology, 35(8) PubMed ID: Cloutier G, Zimmer A, Yu FT, Chiasson JL, "Increased shear rate resistance and fastest kinetics of erythrocyte aggregation in diabetes measured with ultrasound.", Diabetes care, 31(7) PubMed ID: Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F, "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.", The New England journal of medicine, 358(24) PubMed ID:

16 Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, Keltai M, Lonn E, McFarlane S, McQueen M, Teo K, Sheridan P, Bosch J, Pogue J, Yusuf S, "Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.", Diabetes care, 31(5) PubMed ID: Wolever TM, Gibbs AL, Mehling C, Chiasson JL, Connelly PW, Josse RG, Leiter LA, Maheux P, Rabasa-Lhoret R, Rodger NW, Ryan EA, "The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of lowglycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein.", The American journal of clinical nutrition, 87(1) PubMed ID: Chiasson JL, "Prevention of Type 2 diabetes: fact or fiction?", Expert opinion on pharmacotherapy, 8(18) PubMed ID: Costa M, Potvin S, Hammana I, Malet A, Berthiaume Y, Jeanneret A, Lavoie A, Lévesque R, Perrier J, Poisson D, Karelis AD, Chiasson JL, Rabasa- Lhoret R, "Increased glucose excursion in cystic fibrosis and its association with a worse clinical status.", Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 6(6) PubMed ID: Godbout A, Chiasson JL, "Who should benefit from the use of alphaglucosidase inhibitors?", Current diabetes reports, 7(5) PubMed ID: Patel A,, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B, "Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.", Lancet, 370(9590) PubMed ID: Fontaine-Bisson B, Wolever TM, Chiasson JL, Rabasa-Lhoret R, Maheux P, Josse RG, Leiter LA, Rodger NW, Ryan EA, Connelly PW, Corey PN, El-Sohemy A, "Genetic polymorphisms of tumor necrosis factor-alpha modify the association between dietary polyunsaturated fatty acids and fasting HDLcholesterol and apo A-I concentrations.", The American journal of clinical nutrition, 86(3) PubMed ID: Hammana I, Malet A, Costa M, Brochiero E, Berthiaume Y, Potvin S, Chiasson JL, Coderre L, Rabasa-Lhoret R, "Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis.", Diabetes & metabolism, 33(3) PubMed ID:

17 Chui MH, Papanikolaou Y, Fontaine-Bisson B, Turcotte J, Wolever TM, El- Sohemy A, Chiasson JL, Rabasa-Lhoret R, Maheux P, Ryan E, Greenwood CE, "The TNF-alpha-238G > a single-nucleotide polymorphism protects against memory decline in older adults with type 2 diabetes.", Behavioral neuroscience, 121(3) PubMed ID: Fontaine-Bisson B, Wolever TM, Chiasson JL, Rabasa-Lhoret R, Maheux P, Josse RG, Leiter LA, Rodger NW, Ryan EA, El-Sohemy A, "Tumor necrosis factor alpha -238G>A genotype alters postprandial plasma levels of free fatty acids in obese individuals with type 2 diabetes mellitus.", Metabolism: clinical and experimental, 56(5) PubMed ID: Andrulionyte L, Kuulasmaa T, Chiasson JL, Laakso M,, "Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.", Diabetes, 56(4) PubMed ID: Meugnier E, Faraj M, Rome S, Beauregard G, Michaut A, Pelloux V, Chiasson JL, Laville M, Clement K, Vidal H, Rabasa-Lhoret R, "Acute hyperglycemia induces a global downregulation of gene expression in adipose tissue and skeletal muscle of healthy subjects.", Diabetes, 56(4) PubMed ID: Pelletier A, Tardif A, Gingras MH, Chiasson JL, Coderre L, "Chronic exposure to ketone bodies impairs glucose uptake in adult cardiomyocytes in response to insulin but not vanadate: the role of PI3-K.", Molecular and cellular biochemistry, 296(1-2) PubMed ID: Brindisi MC, Hahn J, Chiasson JL, Rabasa-Lhoret R, "Under-utilization of capillary glucose monitoring by type 2 diabetic patients.", Diabetes research and clinical practice, 75(1) PubMed ID: Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR, "Effect of ramipril on the incidence of diabetes.", The New England journal of medicine, 355(15) PubMed ID: Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR, "Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.", Lancet, 368(9541) PubMed ID: Andrulionyte L, Laukkanen O, Chiasson JL, Laakso M,, "Single nucleotide polymorphisms of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus: the STOP-NIDDM trial.", Journal of molecular medicine (Berlin, Germany), 84(8) PubMed ID:

18 Andrulionyte L, Peltola P, Chiasson JL, Laakso M,, "Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.", Diabetes, 55(7) PubMed ID: Sobel BE,, "Ancillary studies in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial: Synergies and opportunities.", The American journal of cardiology, 97(12A) PubMed ID: Albu J, Gottlieb SH, August P, Nesto RW, Orchard TJ,, "Modifications of coronary risk factors.", The American journal of cardiology, 97(12A) PubMed ID: Barsness GW, Gersh BJ, Brooks MM, Frye RL,, "Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.", The American journal of cardiology, 97(12A) PubMed ID: Steiner G,, "Statement of the problem.", The American journal of cardiology, 97(12A) PubMed ID: Magee MF, Isley WL,, "Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.", The American journal of cardiology, 97(12A) PubMed ID: Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, Kelsey SF, Orchard TJ,, "Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.", The American journal of cardiology, 97(12A) PubMed ID: Hlatky MA, Melsop KA, Boothroyd DB,, "Economic evaluation of alternative strategies to treat patients with diabetes mellitus and coronary artery disease.", The American journal of cardiology, 97(12A) PubMed ID: Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J,, "Homocysteine lowering with folic acid and B vitamins in vascular disease.", The New England journal of medicine, 354(15) PubMed ID: Brindisi MC, Rabasa-Lhoret R, Chiasson JL, "Postprandial hyperglycaemia: to treat or not to treat?", Diabetes & metabolism, 32(2) PubMed ID: El Midaoui A, Chiasson JL, Tancrède G, Nadeau A, "Physical training reverses the increased activity of the hepatic ketone body synthesis pathway in chronically diabetic rats.", American journal of physiology. Endocrinology and metabolism, 290(2) PubMed ID:

19 Lonn E, Held C, Arnold JM, Probstfield J, McQueen M, Micks M, Pogue J, Sheridan P, Bosch J, Genest J, Yusuf S,, "Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial.", The Canadian journal of cardiology, 22(1) PubMed ID: Journal Articles 2011/1 Published First Listed Author 2008/ Published Co-Author 2008/ Published Co-Author 2006/ Published First Listed Author Chiasson, J.L. and Bernard, S., "Reducing cardiovascular risk factors in patients with pre-diabetes.", Diabetes Management, 1, Ur, E., Chiasson, J.L., Ransom, T., Rowe, R., "Screening for type 1 and type 2 diabetes.", Can. J. Diabetes, 32(Suppl 1), S14-S16 Ur, E., Chiasson, J.L., Ransom, T., Rowe, R., "Prevention of diabetes.", Can. J. Diabetes, 32(Suppl 1), S17-S19 Chiasson, J.L., "Pharmacological and surgical intervention for the prevention of diabetes.", Nestlé Nutrition Workshop Ser. Clin. Perform. Programme, 11, Book Chapters 2012/ In Press First Listed Author 2012/ In Press Last Author "Decreasing postprandial plasma glucose in subjects with IGT using an # (alpha)-glucosidase inhibitor for the prevention of type 2 diabetes mellitus: The STOP-NIDDM Trial.", Prevention of type 2 diabetes; From Science to Therapies, LeRoith, D., Ed., Springer Science Authors: Chiasson, J.L., Laakso, M., and Hanefeld, M.: "Prevention of type 2 diabetes (chapter 38).", Diabetes in America, NIH Authors: Knowler, B., Chiasson, J.L. Clinical Care Guidelines "2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada" Description / Contribution Value: The purpose of this review was to determine that there was no salient information missing, no conflicting recommendations, and that the recommendations are generally applicable to clinical practice. 19